Cecilie Johannessen Landmark
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cecilie Johannessen Landmark has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
Svein I. Johannessen
Section for Clinical Pharmacology, National Center for Epilepsy, Department of Pharmacology Oslo University Hospital Oslo Norway
22 shared publicationsMargrete Larsen Burns
Section for Clinical Pharmacology, National Center for Epilepsy, Department of Pharmacology Oslo University Hospital Oslo Norway
12 shared publicationsArton Baftiu
The National Center for Epilepsy, Oslo University Hospital, Oslo, Norway
9 shared publicationsErik Sætre
National Center for Epilepsy Oslo University Hospital, Full member of the ERN EpiCare Sandvika Norway
5 shared publicationsKatrine Heger
Department of Pharmacy Faculty of Health Sciences, Oslo Metropolitan University Oslo Norway
4 shared publicationsTorleiv Svendsen
National Center for Epilepsy Oslo University Hospital, Full member of the ERN EpiCare Sandvika Norway
4 shared publications
Latest Publications
- Open Access
Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices ( EILAT XVIII ). I. Treatments in preclinical and early clinical development
Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3–6, 2026. This article provides summaries of eight treatments in preclinical and early clinical development that were presented at EILAT XVIII. These include AUT00206, a positive allosteric modulator of Kv3.1 and Kv3.2 voltage‐gated potassium channels in development for the treatment of rare epilepsy syndromes as well as neurodevelopmental and neuropsychiatric disorders; ION283, an antisense oligonucleotide designed to suppress the expression of glycogen synthase 1, under investigation for the treatment of Lafora disease; MSCA‐7136, a selective allosteric RAS/mitogen‐activated protein kinase—extracellular signal regulated kinase (MEK) inhibitor being developed for the treatment of focal seizures associated with mesial temporal lobe epilepsy and seizures associated with tuberous sclerosis complex; OV329, a selective inhibitor of γ‐aminobutyric acid (GABA) aminotransferase, in development for the treatment of drug‐resistant focal seizures; PTI5803 (probenecid), an uricosuric agent and a blocker of pannexin 1 channels, repurposed as a treatment for seizures associated with focal cortical dysplasia; simufilam, a filamin A modulator under investigation for the treatment of tuberous sclerosis complex‐related epilepsy; SN‐2000, a selective allosteric phosphodiesterase 4B inhibitor, in development for the treatment of focal seizures; and sodium selenate, a promoter of the dephosphorylation of pathological hyperphosphorylated tau in the brain, under investigation as a disease‐modifying agent in mesial temporal lobe epilepsy. Treatments in more advanced clinical development are discussed in an accompanying article.
Open AccessProgress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices ( EILAT XVIII ). I. Treatments in preclinical and early clinical development
Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3–6, 2026. This article provides summaries of eight treatments in preclinical and early clinical development that were presented at EILAT XVIII. These include AUT00206, a positive allosteric modulator of Kv3.1 and Kv3.2 voltage‐gated potassium channels in development for the treatment of rare epilepsy syndromes as well as neurodevelopmental and neuropsychiatric disorders; ION283, an antisense oligonucleotide designed to suppress the expression of glycogen synthase 1, under investigation for the treatment of Lafora disease; MSCA‐7136, a selective allosteric RAS/mitogen‐activated protein kinase—extracellular signal regulated kinase (MEK) inhibitor being developed for the treatment of focal seizures associated with mesial temporal lobe epilepsy and seizures associated with tuberous sclerosis complex; OV329, a selective inhibitor of γ‐aminobutyric acid (GABA) aminotransferase, in development for the treatment of drug‐resistant focal seizures; PTI5803 (probenecid), an uricosuric agent and a blocker of pannexin 1 channels, repurposed as a treatment for seizures associated with focal cortical dysplasia; simufilam, a filamin A modulator under investigation for the treatment of tuberous sclerosis complex‐related epilepsy; SN‐2000, a selective allosteric phosphodiesterase 4B inhibitor, in development for the treatment of focal seizures; and sodium selenate, a promoter of the dephosphorylation of pathological hyperphosphorylated tau in the brain, under investigation as a disease‐modifying agent in mesial temporal lobe epilepsy. Treatments in more advanced clinical development are discussed in an accompanying article.
- Open Access
Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices ( EILAT XVIII ). II . Treatments in more advanced clinical development
This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026. The treatments reviewed include bexicaserin, a selective 5‐hydroxytryptamine (5‐HT, serotonin) type 2C (5‐HT 2C ) receptor superagonist investigated as a treatment for developmental and epileptic encephalopathies (DEEs); BMB‐101, a selective 5‐HT 2C receptor agonist investigated for the treatment of absence seizures and DEEs; elsunersen, an antisense oligonucleotide designed for the treatment of early‐onset SCN2A ‐DEE; EPX‐100 (clemizole hydrochloride), an antihistamine endowed with agonist activity at 5‐HT 2A and 5‐HT 2B receptors, repurposed as a treatment for DEEs; ES‐481, an antagonist of α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) receptors containing the transmembrane AMPA receptor regulatory protein γ8 (TARP‐γ8), under investigation for the treatment of drug‐resistant epilepsy; ETX‐101, a gene therapy in development for the treatment of SCN1A ‐positive Dravet syndrome; PrevEp‐006 (intranasal seletracetam), a synaptic vesicle glycoprotein 2A (SV2A) ligand under investigation as an acute seizure rescue therapy; radiprodil, a negative allosteric modulator that binds to the GluN2B subunit of the N ‐methyl‐ D ‐aspartate (NMDA) receptor, in development for the treatment of seizures and other symptoms associated with GRIN‐related neurodevelopmental disorder, tuberous sclerosis complex, and focal cortical dysplasia type II; RAP‐219, a selective negative allosteric modulator of TARP‐γ8, in development for drug‐resistant focal epilepsy; relutrigine, a selective disease‐state sodium channel modulator investigated as a treatment for SCN2A ‐ and SCN8A ‐DEE; Staccato Alprazolam, a breath‐actuated device that delivers alprazolam to the lungs for rapid seizure termination; vormatrigine, a functionally selective sodium channel modulator in development for the treatment of focal seizures; and zorevunersen, an antisense oligonucleotide engineered to restore endogenous Nav1.1 protein expression, investigated for the treatment of Dravet syndrome. Overall, the evidence reviewed justifies expectations for improved health outcomes for the millions of children and adults with epilepsy who do not fully benefit from existing therapies.
Open AccessProgress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices ( EILAT XVIII ). II . Treatments in more advanced clinical development
This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026. The treatments reviewed include bexicaserin, a selective 5‐hydroxytryptamine (5‐HT, serotonin) type 2C (5‐HT 2C ) receptor superagonist investigated as a treatment for developmental and epileptic encephalopathies (DEEs); BMB‐101, a selective 5‐HT 2C receptor agonist investigated for the treatment of absence seizures and DEEs; elsunersen, an antisense oligonucleotide designed for the treatment of early‐onset SCN2A ‐DEE; EPX‐100 (clemizole hydrochloride), an antihistamine endowed with agonist activity at 5‐HT 2A and 5‐HT 2B receptors, repurposed as a treatment for DEEs; ES‐481, an antagonist of α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) receptors containing the transmembrane AMPA receptor regulatory protein γ8 (TARP‐γ8), under investigation for the treatment of drug‐resistant epilepsy; ETX‐101, a gene therapy in development for the treatment of SCN1A ‐positive Dravet syndrome; PrevEp‐006 (intranasal seletracetam), a synaptic vesicle glycoprotein 2A (SV2A) ligand under investigation as an acute seizure rescue therapy; radiprodil, a negative allosteric modulator that binds to the GluN2B subunit of the N ‐methyl‐ D ‐aspartate (NMDA) receptor, in development for the treatment of seizures and other symptoms associated with GRIN‐related neurodevelopmental disorder, tuberous sclerosis complex, and focal cortical dysplasia type II; RAP‐219, a selective negative allosteric modulator of TARP‐γ8, in development for drug‐resistant focal epilepsy; relutrigine, a selective disease‐state sodium channel modulator investigated as a treatment for SCN2A ‐ and SCN8A ‐DEE; Staccato Alprazolam, a breath‐actuated device that delivers alprazolam to the lungs for rapid seizure termination; vormatrigine, a functionally selective sodium channel modulator in development for the treatment of focal seizures; and zorevunersen, an antisense oligonucleotide engineered to restore endogenous Nav1.1 protein expression, investigated for the treatment of Dravet syndrome. Overall, the evidence reviewed justifies expectations for improved health outcomes for the millions of children and adults with epilepsy who do not fully benefit from existing therapies.
- Open Access
Add‐on treatment with vinpocetine reduces seizure frequency and improves comorbidities in patients with loss‐of‐function γ‐aminobutyric acid type A receptor variants
Objective: The semisynthetic compound vinpocetine has gained attention as a potential precision medicine for developmental and epileptic encephalopathies caused by loss‐of‐function (LoF) variants in γ‐aminobutyric acid type A (GABA A ) receptor genes. As a positive allosteric modulator of GABA A receptors, case reports suggest that vinpocetine can reduce epileptiform activity and seizure frequency, while improving cognitive function in patients with GABA A receptor‐related epilepsies. Here, we extend these observations with a retrospective observational study evaluating the response to vinpocetine in an additional seven patients. Methods: Patients initiated treatment with vinpocetine between 2018 and 2025 at the Danish Epilepsy Centre or abroad. Clinical data were collected from medical records, seizure diaries, and neuropsychological assessments. The modulatory efficacy of vinpocetine was investigated using electrophysiological studies. Results: Nine patients harboring eight GABA A receptor LoF variants were given add‐on vinpocetine treatment. Electrophysiological analyses confirmed dose‐dependent positive modulation by vinpocetine across tested variants. Six patients with a median age of 15.5 years (range = 6–29) continued treatment for a median of 24 months (range = 12–90), whereas three discontinued due to adverse effects (AEs) or lack of efficacy. The patients' level of function ranged from normal to moderate intellectual disability, psychiatric comorbidities, and behavioral disturbances. Four patients initiated vinpocetine due to uncontrolled seizures. One became seizure‐free, and two experienced a 50%–55% reduction. Electroencephalograms demonstrated improved spike–wave indexes in four patients. Six showed improvement in nonseizure factors, and caregivers reported reduced aggressivity and better vocabulary in one. Vinpocetine was well tolerated, with only mild and reversible AEs reported. Significance: Adjunctive vinpocetine shows promise as a targeted therapy for patients with GABA A receptor LoF variants, decreasing seizure frequency and positively impacting nonseizure factors, with only mild AEs reported. Vinpocetine may be a safe and effective therapy for patients with GABA A receptor‐related epilepsies, which should be investigated further in future N ‐of‐1 trials.
Open AccessAdd‐on treatment with vinpocetine reduces seizure frequency and improves comorbidities in patients with loss‐of‐function γ‐aminobutyric acid type A receptor variants
Objective: The semisynthetic compound vinpocetine has gained attention as a potential precision medicine for developmental and epileptic encephalopathies caused by loss‐of‐function (LoF) variants in γ‐aminobutyric acid type A (GABA A ) receptor genes. As a positive allosteric modulator of GABA A receptors, case reports suggest that vinpocetine can reduce epileptiform activity and seizure frequency, while improving cognitive function in patients with GABA A receptor‐related epilepsies. Here, we extend these observations with a retrospective observational study evaluating the response to vinpocetine in an additional seven patients. Methods: Patients initiated treatment with vinpocetine between 2018 and 2025 at the Danish Epilepsy Centre or abroad. Clinical data were collected from medical records, seizure diaries, and neuropsychological assessments. The modulatory efficacy of vinpocetine was investigated using electrophysiological studies. Results: Nine patients harboring eight GABA A receptor LoF variants were given add‐on vinpocetine treatment. Electrophysiological analyses confirmed dose‐dependent positive modulation by vinpocetine across tested variants. Six patients with a median age of 15.5 years (range = 6–29) continued treatment for a median of 24 months (range = 12–90), whereas three discontinued due to adverse effects (AEs) or lack of efficacy. The patients' level of function ranged from normal to moderate intellectual disability, psychiatric comorbidities, and behavioral disturbances. Four patients initiated vinpocetine due to uncontrolled seizures. One became seizure‐free, and two experienced a 50%–55% reduction. Electroencephalograms demonstrated improved spike–wave indexes in four patients. Six showed improvement in nonseizure factors, and caregivers reported reduced aggressivity and better vocabulary in one. Vinpocetine was well tolerated, with only mild and reversible AEs reported. Significance: Adjunctive vinpocetine shows promise as a targeted therapy for patients with GABA A receptor LoF variants, decreasing seizure frequency and positively impacting nonseizure factors, with only mild AEs reported. Vinpocetine may be a safe and effective therapy for patients with GABA A receptor‐related epilepsies, which should be investigated further in future N ‐of‐1 trials.
- Open Access
Clinical validation of a patient‐friendly saliva microsampling approach to monitor perampanel levels in people with epilepsy
Perampanel (PER) is a third‐generation antiseizure medication (ASM) with a well‐established concentration–effect relationship. Saliva represents a non‐invasive alternative to plasma for therapeutic drug monitoring (TDM) of PER, as it reflects the free plasma fraction. Volumetric absorptive microsampling (VAMS) enables standardized, patient‐friendly saliva collection. This study aimed to clinically validate saliva‐VAMS by directly comparing it with conventional liquid saliva sampling for PER quantification. In a prospective study, saliva was collected from 11 people with epilepsy receiving PER therapy (dose range = 2–10 mg/day) using both VAMS and conventional saliva sampling. PER concentrations were measured by liquid chromatography coupled with tandem mass spectrometry and compared using repeated measures Bland–Altman analysis and Lin's concordance correlation coefficient to evaluate agreement between methods. PER concentrations measured in saliva‐VAMS showed excellent agreement with those obtained from conventional saliva sampling, with mean bias of −0.126 ng/mL (95% confidence interval = −0.582 to 0.330). No relevant constant or proportional bias was observed, and limits of agreement were within predefined acceptance criteria. Concordance between methods was high, supporting analytical equivalence. The demonstrated interchangeability between saliva‐VAMS and conventional saliva sampling supports adoption of saliva‐VAMS in clinical TDM workflows, enabling standardized fixed‐volume collection, simplified storage/transport, and potential home‐based sampling for remote dose optimization of PER and potentially other ASMs.
Open AccessClinical validation of a patient‐friendly saliva microsampling approach to monitor perampanel levels in people with epilepsy
Perampanel (PER) is a third‐generation antiseizure medication (ASM) with a well‐established concentration–effect relationship. Saliva represents a non‐invasive alternative to plasma for therapeutic drug monitoring (TDM) of PER, as it reflects the free plasma fraction. Volumetric absorptive microsampling (VAMS) enables standardized, patient‐friendly saliva collection. This study aimed to clinically validate saliva‐VAMS by directly comparing it with conventional liquid saliva sampling for PER quantification. In a prospective study, saliva was collected from 11 people with epilepsy receiving PER therapy (dose range = 2–10 mg/day) using both VAMS and conventional saliva sampling. PER concentrations were measured by liquid chromatography coupled with tandem mass spectrometry and compared using repeated measures Bland–Altman analysis and Lin's concordance correlation coefficient to evaluate agreement between methods. PER concentrations measured in saliva‐VAMS showed excellent agreement with those obtained from conventional saliva sampling, with mean bias of −0.126 ng/mL (95% confidence interval = −0.582 to 0.330). No relevant constant or proportional bias was observed, and limits of agreement were within predefined acceptance criteria. Concordance between methods was high, supporting analytical equivalence. The demonstrated interchangeability between saliva‐VAMS and conventional saliva sampling supports adoption of saliva‐VAMS in clinical TDM workflows, enabling standardized fixed‐volume collection, simplified storage/transport, and potential home‐based sampling for remote dose optimization of PER and potentially other ASMs.
Pharmacokinetic variability and complex two‐way interactions with cenobamate in patients with refractory epilepsy
Objectives: Cenobamate (CNB) is a new antiseizure medication (ASM) for add‐on therapy in adults with refractory epilepsy. The purpose of this study was to investigate the pharmacokinetic variability of CNB and extent of interactions with other ASMs. Methods: In this observational therapeutic drug monitoring (TDM) study we included all patients with serum concentrations of CNB and concomitantly used ASMs (2022–2025) from the Section for Clinical Pharmacology, National Center for Epilepsy, Oslo University Hospital. Results: Data from 258 patients included 672 serum CNB concentration measurements (1–7 per patient; 56% women; median age = 36 years, range = 11–77). Mean daily dose and serum concentration at the most recent measurement were 164 mg/day (range = 12.5–400, SD = 88.6) and 53.7 μmol L −1 (range 5–186, SD = 34.8). Intraindividual variation in CNB concentration/dose (C/D) ratios ranged from 6% to 33% (coefficient of variation = 18%); interpatient variability was 34‐fold. Comedication was a contributing but variable factor. Mean CNB C/D ratios were affected by strong enzyme inducers (−9%) and inhibitors (+14%) as compared to neutral ASMs ( p < .05). Twenty‐four concomitant ASMs were used (1–6 per patient, mean = 1.91, SD = .94); clobazam, lamotrigine, and valproate were the most common. After initiating CNB, significant but variable increases in mean C/D ratios of desmethylclobazam (+233%, and +344% for the Cd‐clb/Cclb€ ratio, n = 57) and phenobarbital (+36%, n = 15) were observed, as were decreases for lamotrigine (−28%, n = 57) and carbamazepine (−26%, n = 7) ( p < .05). For most other ASMs, there were unpredictable changes in individual C/D ratios. Significance: We demonstrate complex and unpredictable two‐way interactions in polytherapy with CNB and pronounced pharmacokinetic variability among patients with refractory epilepsy, elucidating the usefulness of TDM.
Pharmacokinetic variability and complex two‐way interactions with cenobamate in patients with refractory epilepsy
Objectives: Cenobamate (CNB) is a new antiseizure medication (ASM) for add‐on therapy in adults with refractory epilepsy. The purpose of this study was to investigate the pharmacokinetic variability of CNB and extent of interactions with other ASMs. Methods: In this observational therapeutic drug monitoring (TDM) study we included all patients with serum concentrations of CNB and concomitantly used ASMs (2022–2025) from the Section for Clinical Pharmacology, National Center for Epilepsy, Oslo University Hospital. Results: Data from 258 patients included 672 serum CNB concentration measurements (1–7 per patient; 56% women; median age = 36 years, range = 11–77). Mean daily dose and serum concentration at the most recent measurement were 164 mg/day (range = 12.5–400, SD = 88.6) and 53.7 μmol L −1 (range 5–186, SD = 34.8). Intraindividual variation in CNB concentration/dose (C/D) ratios ranged from 6% to 33% (coefficient of variation = 18%); interpatient variability was 34‐fold. Comedication was a contributing but variable factor. Mean CNB C/D ratios were affected by strong enzyme inducers (−9%) and inhibitors (+14%) as compared to neutral ASMs ( p < .05). Twenty‐four concomitant ASMs were used (1–6 per patient, mean = 1.91, SD = .94); clobazam, lamotrigine, and valproate were the most common. After initiating CNB, significant but variable increases in mean C/D ratios of desmethylclobazam (+233%, and +344% for the Cd‐clb/Cclb€ ratio, n = 57) and phenobarbital (+36%, n = 15) were observed, as were decreases for lamotrigine (−28%, n = 57) and carbamazepine (−26%, n = 7) ( p < .05). For most other ASMs, there were unpredictable changes in individual C/D ratios. Significance: We demonstrate complex and unpredictable two‐way interactions in polytherapy with CNB and pronounced pharmacokinetic variability among patients with refractory epilepsy, elucidating the usefulness of TDM.
- Open Access
- 6 October 2025
- Published by Wiley in Epilepsia Open
- Vol. 10 (6) , 1824-1834
Rescue epilepsy medication and training: A comparison between midazolam use, guidelines, clinical practice, and possibilities in the UK and Norway
Objectives: Status epilepticus (SE) is a prolonged epileptic seizure carrying significant risk of long‐term disability and death. Rescue therapies are prescribed for prehospital administration to terminate SE. This study compared prescribing practices of rescue therapies of midazolam in the UK and Norway. Methods: A cross‐sectional, online, 21‐item Likert‐style survey was administered to epilepsy professionals in the UK circulated via ILAE/ESNA and in Norway via ILAE/Epilepsinet using a non‐discriminatory exponential snowballing technique leading to non‐probability sampling. Data were collected anonymously and analyzed using descriptive statistics, Mann–Whitney, Chi‐square, and Fisher's exact tests. Significance was accepted at p < 0.05. Results: All 86 UK and 53 Norway respondents identified buccal midazolam as the first‐line rescue medication choice in the community for prolonged and/or generalized tonic–clonic seizures. Norwegian respondents had significantly more experience in epilepsy‐related work ( p = 0.002), were more likely to have a larger caseload on buccal midazolam ( p < 0.001), prescribed higher midazolam doses ( p < 0.001), and provided training yearly ( p < 0.001). UK respondents were more likely to delegate rescue medication prescribing to primary care ( p = 0.006) and reviewed emergency management plans more frequently ( p = 0.006). There was an inter‐country difference in the period of midazolam non‐use that respondents required before withdrawing from treatment plans ( p < 0.001). Concern about inappropriate use of buccal midazolam was similarly high in both countries. Significance: This study compared epilepsy professionals in two neighboring high‐income countries. Findings suggest an urgent need for international guidelines to recommend best practices on prescribing doses and withdrawal of buccal midazolam. The potential abuse of buccal midazolam by patients and carers warrants further investigation. Plain Language Summary: This study investigated doctors' and nurses' views on the use of epilepsy rescue therapies, particularly midazolam. These are medications that can stop dangerously long epileptic seizures from progressing to the point of serious injury or death. The study was carried out in both the UK and Norway to establish differences between the countries. The key findings were that Norwegian doctors prescribed rescue medications at a higher dose, that UK clinicians reviewed and deprescribed medications faster after patients stopped having prolonged seizures, and that clinicians in both countries were concerned about medications being misused or abused by patients and carers.
- 6 October 2025
- Published by Wiley in Epilepsia Open
- Vol. 10 (6) , 1824-1834
Open AccessRescue epilepsy medication and training: A comparison between midazolam use, guidelines, clinical practice, and possibilities in the UK and Norway
Objectives: Status epilepticus (SE) is a prolonged epileptic seizure carrying significant risk of long‐term disability and death. Rescue therapies are prescribed for prehospital administration to terminate SE. This study compared prescribing practices of rescue therapies of midazolam in the UK and Norway. Methods: A cross‐sectional, online, 21‐item Likert‐style survey was administered to epilepsy professionals in the UK circulated via ILAE/ESNA and in Norway via ILAE/Epilepsinet using a non‐discriminatory exponential snowballing technique leading to non‐probability sampling. Data were collected anonymously and analyzed using descriptive statistics, Mann–Whitney, Chi‐square, and Fisher's exact tests. Significance was accepted at p < 0.05. Results: All 86 UK and 53 Norway respondents identified buccal midazolam as the first‐line rescue medication choice in the community for prolonged and/or generalized tonic–clonic seizures. Norwegian respondents had significantly more experience in epilepsy‐related work ( p = 0.002), were more likely to have a larger caseload on buccal midazolam ( p < 0.001), prescribed higher midazolam doses ( p < 0.001), and provided training yearly ( p < 0.001). UK respondents were more likely to delegate rescue medication prescribing to primary care ( p = 0.006) and reviewed emergency management plans more frequently ( p = 0.006). There was an inter‐country difference in the period of midazolam non‐use that respondents required before withdrawing from treatment plans ( p < 0.001). Concern about inappropriate use of buccal midazolam was similarly high in both countries. Significance: This study compared epilepsy professionals in two neighboring high‐income countries. Findings suggest an urgent need for international guidelines to recommend best practices on prescribing doses and withdrawal of buccal midazolam. The potential abuse of buccal midazolam by patients and carers warrants further investigation. Plain Language Summary: This study investigated doctors' and nurses' views on the use of epilepsy rescue therapies, particularly midazolam. These are medications that can stop dangerously long epileptic seizures from progressing to the point of serious injury or death. The study was carried out in both the UK and Norway to establish differences between the countries. The key findings were that Norwegian doctors prescribed rescue medications at a higher dose, that UK clinicians reviewed and deprescribed medications faster after patients stopped having prolonged seizures, and that clinicians in both countries were concerned about medications being misused or abused by patients and carers.
- Open Access
Availability and affordability of cannabinoids for epilepsy treatment across different geographic settings—A survey from the ILAE Plant‐Based Therapy Task Force
Pharmacoresistant seizures remain a major challenge for the global epilepsy community. Hence, approval of highly purified pharmaceutical grade cannabidiol (CBD) for Dravet syndrome (DS), Lennox–Gastaut syndrome (LGS), and refractory seizures associated with tuberous sclerosis complex (TSC) generated significant interest, both in the medical community and public domain. However, there are limited data on the availability and accessibility of CBD and other cannabinoids for the treatment of drug‐resistant epilepsy worldwide. The International League Against Epilepsy (ILAE) Plant‐Based Therapy Task Force commissioned a working group in 2022 to conduct a survey through the chapters to understand the global availability of cannabinoids for the treatment of epilepsy, and to identify the possible factors affecting the accessibility and affordability of these products. The survey was conducted between June and December 2023. Responses were screened, tabulated, and analyzed using pre‐set criteria. Among the 126 ILAE Chapters, 86 (68%) completed the survey questionnaire. Thirty‐two countries had regulatory approval for cannabinoids for the treatment of epilepsy at the time of this survey, of which 21 (65.6%) reported approval only for CBD. Twenty‐three chapters (71.8%) in this group reported cannabinoids to be unaffordable, and 18 (56.2%) reported they were difficult to access. Cannabinoids were not approved formally for epilepsy in 54 countries (62.7%). Over‐the‐counter availability of unapproved products containing cannabinoids was reported from 34 countries (39.5%). Forty‐seven chapters (54.6%) indicated the existence of traditional plant‐based products for epilepsy in their respective countries, of which 16 had products containing cannabinoids. Forty‐two chapters (48.8%) expressed a need for targeted advocacy efforts from the ILAE to improve the accessibility of cannabinoids for the management of epilepsy. This survey should act as a premise for developing better concerted strategies to improve the availability and affordability of cannabinoids for the management of epilepsy across the world.
Open AccessAvailability and affordability of cannabinoids for epilepsy treatment across different geographic settings—A survey from the ILAE Plant‐Based Therapy Task Force
Pharmacoresistant seizures remain a major challenge for the global epilepsy community. Hence, approval of highly purified pharmaceutical grade cannabidiol (CBD) for Dravet syndrome (DS), Lennox–Gastaut syndrome (LGS), and refractory seizures associated with tuberous sclerosis complex (TSC) generated significant interest, both in the medical community and public domain. However, there are limited data on the availability and accessibility of CBD and other cannabinoids for the treatment of drug‐resistant epilepsy worldwide. The International League Against Epilepsy (ILAE) Plant‐Based Therapy Task Force commissioned a working group in 2022 to conduct a survey through the chapters to understand the global availability of cannabinoids for the treatment of epilepsy, and to identify the possible factors affecting the accessibility and affordability of these products. The survey was conducted between June and December 2023. Responses were screened, tabulated, and analyzed using pre‐set criteria. Among the 126 ILAE Chapters, 86 (68%) completed the survey questionnaire. Thirty‐two countries had regulatory approval for cannabinoids for the treatment of epilepsy at the time of this survey, of which 21 (65.6%) reported approval only for CBD. Twenty‐three chapters (71.8%) in this group reported cannabinoids to be unaffordable, and 18 (56.2%) reported they were difficult to access. Cannabinoids were not approved formally for epilepsy in 54 countries (62.7%). Over‐the‐counter availability of unapproved products containing cannabinoids was reported from 34 countries (39.5%). Forty‐seven chapters (54.6%) indicated the existence of traditional plant‐based products for epilepsy in their respective countries, of which 16 had products containing cannabinoids. Forty‐two chapters (48.8%) expressed a need for targeted advocacy efforts from the ILAE to improve the accessibility of cannabinoids for the management of epilepsy. This survey should act as a premise for developing better concerted strategies to improve the availability and affordability of cannabinoids for the management of epilepsy across the world.
- Open Access
Folate transfer across the placenta during late pregnancy in women with epilepsy: A cross‐sectional, two‐center study
Objective: In women with epilepsy who are treated with antiseizure medications (ASMs), folate concentrations in maternal serum may not be a good indicator of fetal folate supply, because ASMs can interfere with folate handling by the placenta. We aimed to assess the transplacental folate transfer at birth in persons with epilepsy in comparison to controls with no known epilepsy and identify factors affecting it. Methods: This was a cross‐sectional, two‐center study, involving 22 pregnant women with epilepsy treated with ASMs, 10 nontreated pregnant women with epilepsy, and 19 control pregnant individuals with no known epilepsy. Maternal venous blood and umbilical cord blood samples were collected at delivery. Folate concentrations were measured using a validated chemiluminescence assay. ASM concentrations were analyzed in serum and umbilical cord blood. Results: Maternal and neonatal characteristics were generally comparable across the study groups, but cesarian sections were more frequent among controls ( p < .001). Folate concentrations in maternal serum were lower than recommended levels in nine of 26 (35%) of women with epilepsy and eight of 19 (42%) controls. Median cord/maternal serum folate ratios were 1.51 (95% confidence interval [CI] = .92–6.35; n = 17) in women with epilepsy treated with ASMs and 2.02 (95% CI = 1.69–3.71; n = 19) in controls. In women with epilepsy, placental folate transfer was saturable (Cmax = 131.1 ng/mL, 95% CI = 96.4–190.5 ng/mL; Michaelis‐Menten constant, Km = 32.6 ng/mL, 95% CI = 12.5–76.9 ng/mL; adjusted R 2 = .70). Predictability of cord values improved upon exclusion of preterm births (Cmax = 125.2 ng/mL, 95% CI = 97.4–164.7 ng/mL; Km =41.1 ng/mL, 95% CI = 22.4–71.1 ng/mL; adjusted R 2 = .78). Significance: Folate delivery to the fetus during late pregnancy is primarily explained by its concentrations in maternal circulation. In persons with epilepsy, it may be saturable. The frequent apparent folate deficiency observed in our cohort highlights the importance of folate supplementation and monitoring of its levels in maternal circulation throughout pregnancy.
Open AccessFolate transfer across the placenta during late pregnancy in women with epilepsy: A cross‐sectional, two‐center study
Objective: In women with epilepsy who are treated with antiseizure medications (ASMs), folate concentrations in maternal serum may not be a good indicator of fetal folate supply, because ASMs can interfere with folate handling by the placenta. We aimed to assess the transplacental folate transfer at birth in persons with epilepsy in comparison to controls with no known epilepsy and identify factors affecting it. Methods: This was a cross‐sectional, two‐center study, involving 22 pregnant women with epilepsy treated with ASMs, 10 nontreated pregnant women with epilepsy, and 19 control pregnant individuals with no known epilepsy. Maternal venous blood and umbilical cord blood samples were collected at delivery. Folate concentrations were measured using a validated chemiluminescence assay. ASM concentrations were analyzed in serum and umbilical cord blood. Results: Maternal and neonatal characteristics were generally comparable across the study groups, but cesarian sections were more frequent among controls ( p < .001). Folate concentrations in maternal serum were lower than recommended levels in nine of 26 (35%) of women with epilepsy and eight of 19 (42%) controls. Median cord/maternal serum folate ratios were 1.51 (95% confidence interval [CI] = .92–6.35; n = 17) in women with epilepsy treated with ASMs and 2.02 (95% CI = 1.69–3.71; n = 19) in controls. In women with epilepsy, placental folate transfer was saturable (Cmax = 131.1 ng/mL, 95% CI = 96.4–190.5 ng/mL; Michaelis‐Menten constant, Km = 32.6 ng/mL, 95% CI = 12.5–76.9 ng/mL; adjusted R 2 = .70). Predictability of cord values improved upon exclusion of preterm births (Cmax = 125.2 ng/mL, 95% CI = 97.4–164.7 ng/mL; Km =41.1 ng/mL, 95% CI = 22.4–71.1 ng/mL; adjusted R 2 = .78). Significance: Folate delivery to the fetus during late pregnancy is primarily explained by its concentrations in maternal circulation. In persons with epilepsy, it may be saturable. The frequent apparent folate deficiency observed in our cohort highlights the importance of folate supplementation and monitoring of its levels in maternal circulation throughout pregnancy.
A precision approach to therapeutic drug monitoring of valproate to evaluate markers of toxicity
Objective: Treatment with valproic acid (VPA) is associated with risk of liver toxicity. The aim of this study was to use a precision approach to investigate pharmacokinetic variability of both total and unbound serum concentrations of VPA and perform complementary biochemical analyses to evaluate possible markers of toxicity in a clinical setting. Methods: Therapeutic drug monitoring (TDM) data (2018–2022) including total and free unbound serum concentrations of VPA, measurements of concomitantly used antiseizure medications, and biochemical analyses of ammonia and liver enzymes were used. Results: We included 704 measurements from 288 patients (131/157 female/male, median age = 25 years, range = 0–74). Median VPA dose was 1050 mg/day (range = 150–3900); total and unbound VPA concentrations were 430 μmol·L −1 (range = 57–866) and 44 μmol·L −1 (range = 15–125), respectively. Extensive pharmacokinetic intraindividual variability of VPA was observed with long‐term TDM, the coefficient of variability being 21% (range = 6%–55%) in those with five or more measurements ( n = 31). Comedication was noted in 85%, where lamotrigine, clobazam, or levetiracetam were most common. Enzyme inducers/inhibitors and age affected the concentration/dose ratio of both total and unbound VPA. There was a significant linear correlation between total exposure of VPA ( n = 379; r 2 = .014, p < .05) and ammonia levels but the correlation was not significant with unbound VPA ( n = 189; r 2 = .0045). Supplementary clinical data were studied in 16 patients with high ammonia levels (>85 μmol·L −1 ), and 14 of 16 had signs of toxicity. Serum alanine aminotransferase (ALT) was not correlated with total/unbound VPA concentrations, and no one had a greater than threefold increase in ALT as a sign of toxicity. Significance: Combined use of TDM including total and unbound VPA serum concentrations and biochemical analyses of ammonia and liver enzymes are useful as tailored precision monitoring to aid clinical decision‐making in patients with suspected symptoms of toxicity.
A precision approach to therapeutic drug monitoring of valproate to evaluate markers of toxicity
Objective: Treatment with valproic acid (VPA) is associated with risk of liver toxicity. The aim of this study was to use a precision approach to investigate pharmacokinetic variability of both total and unbound serum concentrations of VPA and perform complementary biochemical analyses to evaluate possible markers of toxicity in a clinical setting. Methods: Therapeutic drug monitoring (TDM) data (2018–2022) including total and free unbound serum concentrations of VPA, measurements of concomitantly used antiseizure medications, and biochemical analyses of ammonia and liver enzymes were used. Results: We included 704 measurements from 288 patients (131/157 female/male, median age = 25 years, range = 0–74). Median VPA dose was 1050 mg/day (range = 150–3900); total and unbound VPA concentrations were 430 μmol·L −1 (range = 57–866) and 44 μmol·L −1 (range = 15–125), respectively. Extensive pharmacokinetic intraindividual variability of VPA was observed with long‐term TDM, the coefficient of variability being 21% (range = 6%–55%) in those with five or more measurements ( n = 31). Comedication was noted in 85%, where lamotrigine, clobazam, or levetiracetam were most common. Enzyme inducers/inhibitors and age affected the concentration/dose ratio of both total and unbound VPA. There was a significant linear correlation between total exposure of VPA ( n = 379; r 2 = .014, p < .05) and ammonia levels but the correlation was not significant with unbound VPA ( n = 189; r 2 = .0045). Supplementary clinical data were studied in 16 patients with high ammonia levels (>85 μmol·L −1 ), and 14 of 16 had signs of toxicity. Serum alanine aminotransferase (ALT) was not correlated with total/unbound VPA concentrations, and no one had a greater than threefold increase in ALT as a sign of toxicity. Significance: Combined use of TDM including total and unbound VPA serum concentrations and biochemical analyses of ammonia and liver enzymes are useful as tailored precision monitoring to aid clinical decision‐making in patients with suspected symptoms of toxicity.
- Open Access
- 26 February 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 165, 110340
What do pharmacists know about epilepsy and antiseizure medications? − A survey among pharmacists in Norway
- 26 February 2025
- Published by Elsevier in Epilepsy & Behavior
- Vol. 165, 110340
Open AccessWhat do pharmacists know about epilepsy and antiseizure medications? − A survey among pharmacists in Norway